Get the Stockscreener App
1.30
0.76%
-0.01
After Hours:
1.30
Pulmonx Corp stock is traded at $1.30, with a volume of 690.81K.
It is down -0.76% in the last 24 hours and down -20.25% over the past month.
Pulmonx Corpa is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). Its solution, comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The company has a single reportable and operating segment structure. Geographically in the USA, Europe, the Middle East, and Africa (EMEA), Asia Pacific, and Other International, with the majority of revenue from the USA.
See More
Previous Close:
$1.31
Open:
$1.32
24h Volume:
690.81K
Relative Volume:
1.33
Market Cap:
$54.91M
Revenue:
$90.50M
Net Income/Loss:
$-54.00M
P/E Ratio:
-0.9777
EPS:
-1.3296
Net Cash Flow:
$-32.90M
1W Performance:
-12.16%
1M Performance:
-20.25%
6M Performance:
-23.98%
1Y Performance:
-81.10%
1-Day Range:
$1.28
$1.3597
1-Week Range:
$1.28
$1.54
52-Week Range:
$1.28
$7.17
Pulmonx Corp Stock (LUNG) Company Profile
Name
Pulmonx Corp
Sector
Industry
Phone
650-364-0400
Address
700 CHESAPEAKE DRIVE, REDWOOD CITY
Compare LUNG vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LUNG
Pulmonx Corp
|
1.30 | 55.33M | 90.50M | -54.00M | -32.90M | -1.3296 |
ABT
Abbott Laboratories
|
104.83 | 180.82B | 44.33B | 6.50B | 7.40B | 3.717 |
SYK
Stryker Corp
|
327.65 | 125.72B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
87.89 | 111.16B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
69.78 | 101.28B | 20.08B | 2.89B | 3.66B | 1.9391 |
EW
Edwards Lifesciences Corp
|
82.67 | 47.45B | 6.07B | 1.06B | 1.34B | 1.8063 |
Pulmonx Corp Stock (LUNG) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-31-25 | Downgrade | Piper Sandler | Overweight → Neutral |
| Mar-10-25 | Initiated | D. Boral Capital | Buy |
| Dec-11-24 | Downgrade | Citigroup | Buy → Neutral |
| Jun-04-24 | Initiated | Lake Street | Buy |
| Feb-23-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Sep-05-23 | Initiated | Craig Hallum | Buy |
| Feb-27-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jan-03-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-12-22 | Upgrade | Citigroup | Neutral → Buy |
| Jul-11-22 | Downgrade | Citigroup | Buy → Neutral |
| Mar-02-22 | Resumed | BofA Securities | Neutral |
| Dec-08-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Apr-01-21 | Initiated | Citigroup | Buy |
| Mar-25-21 | Initiated | Piper Sandler | Neutral |
| Mar-10-21 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-04-21 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-26-20 | Initiated | BofA Securities | Buy |
| Oct-26-20 | Initiated | Canaccord Genuity | Buy |
| Oct-26-20 | Initiated | Morgan Stanley | Equal-Weight |
| Oct-26-20 | Initiated | Stifel | Buy |
| Oct-26-20 | Initiated | Wells Fargo | Equal Weight |
View All
Pulmonx Corp Stock (LUNG) Latest News
MACD Signal: Is Pulmonx Corporation stock trending bullish2026 Volatility Report & Verified Short-Term Plans - baoquankhu1.vn
If You Invested $1,000 in Pulmonx Corp (LUNG) - Stock Titan
How The Pulmonx (LUNG) Narrative Is Resetting Around Execution Risks And Fair Value Assumptions - Yahoo Finance
LUNG SEC FilingsPulmonx Corp 10-K, 10-Q, 8-K Forms - Stock Titan
Pulmonx Corp Stock (ISIN: US74586W1018) Trades at Multi-Year Lows Amid Growth Potential in Lung Ther - AD HOC NEWS
Growth Value: Should I set a stop loss on Pulmonx CorporationBull Run & Real-Time Volume Analysis Alerts - baoquankhu1.vn
LUNG Stock Price, Quote & Chart | PULMONX CORP (NASDAQ:LUNG) - ChartMill
Pulmonx Corporation 2025 Annual Report: Innovative COPD Solutions, Zephyr Valve Clinical Data, and Global Market Strategy - Minichart
LUNG Technical Analysis & ETF Price Forecast - Intellectia AI
Pulmonx (NASDAQ: LUNG) expands emphysema device business but remains unprofitable - Stock Titan
Pulmonx 2025 10-K: Revenue $90.5M, EPS (Loss) $(1.33) - TradingView
Pulmonx Corporation (LUNG) Releases Q4 2025 Earnings: Revenue Down, Diluted Loss Per Share Widens - Quiver Quantitative
Soleus group holds 2.67M Pulmonx shares (LUNG) — 6.5% stake disclosed - Stock Titan
Pulmonx Corporation (NASDAQ:LUNG) Q4 2025 Earnings Call Transcript - Insider Monkey
Pulmonx (LUNG): Canaccord Genuity Maintains Buy Rating, Lowers P - GuruFocus
LUNG: Analyst Jason Kolbert Maintains 'Buy' Rating with $14 Targ - GuruFocus
Pulmonx (NASDAQ:LUNG) Given "Buy" Rating at D. Boral Capital - MarketBeat
Pulmonx Corporation Q4 2025 Earnings Call Summary - Yahoo Finance
Pulmonx Secures $60 Million Senior Secured Term Loan From Perceptive; $40 Million Drawn - TradingView
Pulmonx Corp (LUNG) Q4 2025 Earnings Call Highlights: Strategic - GuruFocus
Pulmonx (NASDAQ:LUNG) Insider Sells $11,056.76 in Stock - MarketBeat
Earnings call transcript: Pulmonx Q4 2025 EPS beats, revenue misses, stock dips By Investing.com - Investing.com South Africa
Pulmonx (LUNG) general counsel sells shares, receives 150,000 RSU grant - Stock Titan
Pulmonx Q4 Earnings Call Highlights - Yahoo Finance
Pulmonx Corporation (LUNG) Posts Fourth Quarter Loss, Surpasses Revenue Projections - Bitget
Pulmonx closes $60M credit facility with Perceptive Advisors - Investing.com
Pulmonx closes $60 million credit facility with Perceptive - Investing.com
Pulmonx (LUNG) Q4 2025 Earnings Call Transcript - AOL.com
Earnings call transcript: Pulmonx Q4 2025 EPS beats, revenue misses, stock dips - Investing.com Australia
Pulmonx Corporation (LUNG) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
Pulmonx (LUNG) Exceeds Q4 Revenue Expectations with Strategic Gr - GuruFocus
Pulmonx (LUNG) Projects 2026 Financial Outlook with Revenue and Margin Targets - GuruFocus
Pulmonx earnings beat by $0.14, revenue fell short of estimates - Investing.com
Pulmonx Corporation Reports Fourth Quarter and Full Year 2025 Financial Results, Highlights Transition and Strategic Focus for 2026 - Quiver Quantitative
Earnings Summary: Pulmonx Q4 - Benzinga
Lung device maker Pulmonx trims losses, guides 2026 sales to $90–92M - Stock Titan
Pulmonx Announces Closing of up to $60 Million Credit Facility - Yahoo Finance
Earnings Preview For Pulmonx - Benzinga
LUNG Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
LUNG Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
LUNG Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Pulmonx to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026 - Bitget
Analyst Jason Kolbert Maintains Buy Rating for Pulmonx (LUNG) at $14 Target | LUNG Stock News - GuruFocus
Pulmonx's (LUNG) "Buy" Rating Reiterated at D. Boral Capital - MarketBeat
Pulmonx Corporation to Announce Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026 - Quiver Quantitative
Pulmonx Stock Pops on Takeover Deal: Cash Exit or Hold Out? - AD HOC NEWS
Pulmonx Corporation (NASDAQ:LUNG) Given Average Recommendation of "Hold" by Analysts - MarketBeat
Will Pulmonx Corporation stock outperform Dow Jones index2025 Biggest Moves & Daily Growth Stock Investment Tips - mfd.ru
Pulmonx Stock Under Pressure: Can A Niche Lung-Health Innovator Breathe New Life Into Its Shares? - AD HOC NEWS
Will Pulmonx Corporation stock beat EPS estimatesWeekly Risk Summary & Stock Portfolio Risk Control - mfd.ru
Pulmonx (LUNG) Expected to Announce Earnings on Wednesday - Defense World
Pulmonx Corp Stock (LUNG) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):